Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Asset Writedowns and Impairment: 2018-2023

  • Summit Therapeutics' Asset Writedowns and Impairment was N/A to $474,000 in Q1 2023 from the same period last year, while for Mar 2023 it was $14.9 million, marking a year-over-year change of. This contributed to the annual value of $474,000 for FY2023, which is 94.40% down from last year.
  • Summit Therapeutics' Asset Writedowns and Impairment amounted to $474,000 in Q1 2023, which was down 94.40% from $8.5 million recorded in Q4 2022.
  • Summit Therapeutics' Asset Writedowns and Impairment's 5-year high stood at $8.5 million during Q4 2022, with a 5-year trough of $474,000 in Q1 2023.
  • Moreover, its 2-year median value for Asset Writedowns and Impairment was $4.5 million (2022), whereas its average is $4.5 million.
  • Data for Summit Therapeutics' Asset Writedowns and Impairment shows a peak YoY soared of 195.14% (in 2019) over the last 5 years.
  • Over the past 4 years, Summit Therapeutics' Asset Writedowns and Impairment (Quarterly) stood at $5.1 million in 2019, then followed by $859,000 in 2020, then followed by $8.5 million in 2022, then followed by $474,000 in 2023.
  • Its Asset Writedowns and Impairment stands at $474,000 for Q1 2023, versus $8.5 million for Q4 2022 and $859,000 for Q3 2020.